SOB100 is the first proprietary platform “HLA-G targeted exosome” successfully developed by ShineOn, poised for scalable industrial production in novel drug development. The design of SOB100 received positive feedback from FDA.
HLA-G serves not only as an immune checkpoint but also as a neo tumor target, highly overexpressed on various tumor cells. Exosomes engineered with HLA-G-specific nanoantibodies precisely navigate exosome to tumor cells expressing HLA-G. The innovation of SOB100, “HLA-G targeted exosome”, position ShineOn at forefront of advancing novel therapeutics by featuring three unique technological highlights:
1) Exosome drug delivery carriers targeting HLA-G;
2) Multifunctional HLA-G targeted exosomal anti-cancer drugs;
3) Top ten globally in exosome-based biotech company for new drug development.